Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
Oncotarget. 2015 Sep 8;6(26):22496-512. doi: 10.18632/oncotarget.4318.
Oncotarget. 2015.
PMID: 26101915
Free PMC article.